AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2721103
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of disulfiram daily
Trial: 6368445
Drug: Antacid mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid mixture
Trial: 783029
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by small quantities of antacids
Trial: 28471731
Drug: Ashwagandha root
RxNorm normalized name: ashwagandha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha root extract (300mg twice daily)
Trial: 23810269
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity (DPA) assessment using DigiWalker SW-200
Trial: 11422002
Drug: Itraconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (400 mg on the first day then 200 mg day‐1 for 3 days)
Trial: 9288700
Drug: Thyroid stimulating
RxNorm normalized name: Thyroid stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid stimulating hormone and triiodothyronine
Trial: 8391792
Drug: Subcutaneous enoxaparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin, given twice daily
Trial: 8391792
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous unfractionated heparin (UFH), adjusted-dose
Trial: 27362245
Drug: Purified Vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vero Cell Rabies Vaccine (PVRV), n = 702, 5-dose regimen
Trial: 27362245
Drug: Purified Chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Chick Embryo Cell Vaccine (PCECV), n = 747, 5-dose regimen
Trial: 27362245
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both vaccines
Trial: 25224610
Drug: ARV-based prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV-based prevention (tenofovir gel, oral tenofovir, oral Truvada)
Trial: 22926209
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (160 U, 320 U, or 640 U antigen per dose)
Trial: 22926209
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (2 doses)
Trial: 22926209
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (1 dose)
Trial: 16000352
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (5 to 10 ppm)
Trial: 8891887
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aspirin once daily for 2 weeks
Trial: 8891887
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ticlopidine twice daily for 2 weeks
Trial: 1671940
Drug: HIVAC‐1e vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVAC‐1e vaccine
Trial: 6147412
Drug: Bromazepam 3
RxNorm normalized name: bromazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 3 mg, three times daily
Trial: 6147412
Drug: Bromazepam 6
RxNorm normalized name: bromazepam 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 6 mg, three times daily
Trial: 6147412
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg, three times daily
Trial: 12660517
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) therapy
Trial: 21135365
Drug: Aspirin 162
RxNorm normalized name: aspirin 162 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 162 mg plus clopidogrel 75 mg daily
Trial: 21135365
Drug: Aspirin 162
RxNorm normalized name: aspirin 162 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 162 mg plus placebo daily
Trial: 9081959
Drug: Pralidoxime (PAM)
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pralidoxime (PAM) infusion, 1 gm 8 hourly for four days (total 12 gms)
Trial: 9081959
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of Pralidoxime (PAM), 1 gm immediately after admission
Trial: 2528826
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy with lidocaine
Trial: 2528826
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy with lidocaine combined with a steroid
Trial: 2528826
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray with acupressure
Trial: 2528826
Drug: Therapy without
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy without injected medication
Trial: 1067749
Drug: Zinc therapy
RxNorm normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc therapy (90 mg Zn2+ daily as zinc sulphate by mouth during the latter part of pregnancy)
Trial: 1067749
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no zinc therapy)
Trial: 28383410
Drug: Significant Histological
RxNorm normalized name: Entamoeba histolytica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Significant Histological Model (SHM) scoring system using serum AST, PLT, ALB, and HBV DNA (log10 IU/mL) levels
Trial: 23980351
Drug: Yiqi Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huoxue Recipe (YHR) combined with Western drugs
Trial: 16701188
Drug: Preincisional (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional (10 mL) and postoperative (10 mL) wound infiltration of 0.5% bupivacaine (group 1)
Trial: 16701188
Drug: Preincisional bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional bupivacaine (10 mL) and postoperative infiltration of placebo (normal saline solution) (group 2)
Trial: 16701188
Drug: Preincisional placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional placebo (10 mL) and postoperative bupivacaine (10 mL) (group 3)
Trial: 16701188
Drug: Preincisional (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional (10 mL) and postoperative infiltration of placebo (10 mL) (group 4)
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours) for 14 days
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours) for 7 days
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours) for 6 days
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours) for 13 days
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours) for 7 days (discontinued)
Trial: 8163717
Drug: Moricizine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (250 mg every 8 hours)
Trial: 29724590
Drug: PFNA Augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFNA Augmentation group
Trial: 26271050
Drug: Single-dose ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Trial: 26271050
Drug: Single-dose ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Trial: 26271050
Drug: Multiple-dose ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Trial: 26271050
Drug: Multiple-dose ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Trial: 21414384
Drug: Circumferential matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential matrix system in combination with a retainer (Tofflemire)
Trial: 17144123
Drug: Indomethacin in
RxNorm normalized name: indomethacin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin in usual doses (administered in addition to standard therapy)
Trial: 17144123
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (without indomethacin)
Trial: 14512803
Drug: Poly E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly E ointment applied locally to 27 patients twice a week
Trial: 14512803
Drug: Poly E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly E ointment plus poly E capsule therapy
Trial: 14512803
Drug: Poly E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly E capsule therapy
Trial: 14512803
Drug: EGCG capsule
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG capsule therapy
Trial: 14512803
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with green tea extracts
Trial: 7996367
Drug: IVIG (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (500 mg/kg)
Trial: 9179429
Drug: Inhaled magnesium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled magnesium sulphate (180 mg)
Trial: 8473554
Drug: Experimental lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental lipid emulsion formulation of danazol (fasted)
Trial: 8473554
Drug: Commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial formulation (hard gelatin capsule) (fasted)
Trial: 8473554
Drug: Commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial formulation (hard gelatin capsule) (fed)
Trial: 8473554
Drug: Experimental lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental lipid emulsion formulation of danazol (with food)
Trial: 23839118
Drug: Local lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local lidocaine injection
Trial: 19199072
Drug: Local saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local saline injection (control)
Trial: 7856527
Drug: Stable background
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable background therapy
Trial: 31648501
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with standard first-line chemotherapy
Trial: 26215950
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (90 mg/m² per week for six cycles of 28 days each; arm A)
Trial: 26215950
Drug: Paclitaxel combined
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel combined with bevacizumab (10 mg/kg once every 2 weeks; arm B)
Trial: 24268858
Drug: Low‐fluence photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐fluence photodynamic therapy (PDT)
Trial: 22172912
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (RadiaPlex)
Trial: 22172912
Drug: Petrolatum gel
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum gel (Aquaphor)
Trial: 19240602
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for unruptured MCA aneurysms
Trial: 19240602
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for ruptured MCA aneurysms
Trial: 19240602
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for both unruptured and ruptured MCA aneurysms
Trial: 8726155
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI) - 2 puffs or 200 micrograms
Trial: 1559290
Drug: Daily wear
RxNorm normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily wear or extended wear schedule
Trial: 30411125
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion project (6 months duration)
Trial: 31967678
Drug: Hyperthermic intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) added to interval cytoreductive surgery (CRS)
Trial: 20495139
Drug: Phenylephrine 75
RxNorm normalized name: GUAIFENESIN 400MG/PHENYLEPHRINE 75MG TAB,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 75 μg/min
Trial: 20495139
Drug: Phenylephrine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (all doses)
Trial: 19114405
Drug: COF (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COF (250 mL of black coffee)
Trial: 19114405
Drug: COF+SUC (black
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COF+SUC (black coffee sweetened with 10 g of sucrose)
Trial: 19114405
Drug: SUC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUC (10 g sucrose)
Trial: 15953302
Drug: Therapist-administered relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapist-administered relaxation training
Trial: 15953302
Drug: School-nurse administered
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-nurse administered relaxation training
Trial: 10029463
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the most sensitive clinical items
Trial: 8985221
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide vaccine
Trial: 1745841
Drug: Bromhexine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine (30 mg capsules three times daily)
Trial: 1745841
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched placebo capsules)
Trial: 7050705
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (180 g) in divided doses over three days after phenobarbital infusion
Trial: 31060589
Drug: Psychologically informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychologically informed physical therapy (PIPT) training program
Trial: 24691853
Drug: Topical sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sucralfate four times a day for 7 days
Trial: 19846848
Drug: Higher-intensity continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-intensity continuous renal-replacement therapy (40 ml/kg/hour)
Trial: 19846848
Drug: Lower-intensity continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-intensity continuous renal-replacement therapy (25 ml/kg/hour)
Trial: 19846848
Drug: Higher-intensity continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-intensity continuous renal-replacement therapy
Trial: 19846848
Drug: Lower-intensity continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-intensity continuous renal-replacement therapy
Trial: 17367361
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after the first month post-implant
Trial: 16379582
Drug: Anatibant 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatibant 3.75 mg
Trial: 16379582
Drug: Anatibant 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatibant 22.5 mg
Trial: 16379582
Drug: Anatibant (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatibant (both doses)
Trial: 2504034
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (Li) added to tricyclic antidepressant
Trial: 975039
Drug: Weekly combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly combination chemotherapy
Trial: 975039
Drug: Intermittent combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent combination chemotherapy
Trial: 975039
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (both weekly and intermittent)
Trial: 30560426
Drug: Synbiotic capsule
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic capsule (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each, plus 0.8 g/day of inulin)
Trial: 30560426
Drug: Synbiotic capsule
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic capsule
Trial: 28459958
Drug: TRV027 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 5 mg/h
Trial: 28459958
Drug: TRV027 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 25 mg/h
Trial: 26036529
Drug: Steroid-free regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids for 3 days)
Trial: 26036529
Drug: Steroid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid maintenance regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids maintenance)
Trial: 26036529
Drug: Steroid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid maintenance regimen
Trial: 22384550
Drug: Weifuchun Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weifuchun Pill
Trial: 19211408
Drug: EUSOL (Edinburgh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUSOL (Edinburgh University Solution of Lime)
Trial: 8026054
Drug: Intracoronary urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary urokinase (250,000 U in divided doses)
Trial: 8026054
Drug: Intracoronary urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary urokinase (500,000 U in divided doses)
Trial: 4138966
Drug: CCNU (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCNU (130 mg/m2 orally every 6 weeks)
Trial: 4138966
Drug: 5 azacytidine
RxNorm normalized name: 5 azacytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 azacytidine (60 mg/m2 intravenously daily for 10 days and twice weekly thereafter)
Trial: 4138966
Drug: Cyclophosphamide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (two dose schedules)
Trial: 26154454
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) application (6J)
Trial: 23454058
Drug: Boceprevir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir (400 mg TID)
Trial: 18434021
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (1 ml, 25%)
Trial: 12971247
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents and/or combination therapies
Trial: 10233189
Drug: RBC400OM: RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC400OM: RBC 400 mg b.d., oxytetracycline 500 mg q.d.s.
Trial: 10233189
Drug: RBC400SM: RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC400SM: RBC 400 mg b.d., spiramycin 1 g q.d.s.
Trial: 10233189
Drug: RBC200OM: RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC200OM: RBC 200 mg q.d.s., oxytetracycline 500 mg q.d.s.
Trial: 10233189
Drug: RBC200SM: RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC200SM: RBC 200 mg q.d.s., spiramycin 1 g q.d.s.
Trial: 9119918
Drug: Risperidone 4-16
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4-16 mg/day
Trial: 9119918
Drug: Haloperidol 10-20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 10-20 mg/day